Iron chelation: an adjuvant therapy to target metabolism, growth and survival of murine PTEN-deficient T lymphoma and human T lymphoblastic leukemia/lymphoma

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Lum JJ, Hatzivassiliou G, et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11–20.
   PubMed Web of Science ®Google Scholar
• Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12:21–35.
   PubMed Web of Science ®Google Scholar
• Gutierrez A, Sanda T, Grebliunaite R, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009;114:647–650.
   PubMed Web of Science ®Google Scholar
• Polak R, Buitenhuis M. The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood. 2012;119:911–923.
   PubMed Web of Science ®Google Scholar
• Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356–362.
   PubMed Web of Science ®Google Scholar
• Hagenbeek TJ, Spits H. T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus. Leukemia. 2008;22:608–619.
   PubMed Web of Science ®Google Scholar
• Neckers LM, Trepel JB. Transferrin receptor expression and the control of cell growth. Cancer Invest. 1986;4:461–470.
   PubMed Web of Science ®Google Scholar
• Brock JH. The role of transferrin in lymphocyte transformation. Haematologia (Budap). 1984;17:187–198.
   PubMedGoogle Scholar
• Kelly AP, Finlay DK, Hinton HJ, et al. Notch-induced T cell development requires phosphoinositide-dependent kinase 1. EMBO J. 2007;26:3441–3450.
   PubMed Web of Science ®Google Scholar
• Miethke M, Marahiel MA. Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev. 2007;71:413–451.
   PubMed Web of Science ®Google Scholar
• Inoue S, Kawanishi S. Hydroxyl radical production and human DNA damage induced by ferric nitrilotriacetate and hydrogen peroxide. Cancer Res. 1987;47:6522–6527.
   PubMed Web of Science ®Google Scholar
• Campbell JA. Effects of precipitated silica and of iron oxide on the incidence of primary lung tumours in mice. Br Med J. 1940;2:275–280.
   PubMedGoogle Scholar
• Richmond HG. Induction of sarcoma in the rat by iron-dextran complex. Br Med J. 1959;1:947–949.
   PubMed Web of Science ®Google Scholar
• Stevens RG, Jones DY, Micozzi MS, et al. Body iron stores and the risk of cancer. N Engl J Med. 1988;319:1047–1052.
   PubMed Web of Science ®Google Scholar
• Osborne NJ, Gurrin LC, Allen KJ, et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology. 2010;51:1311–1318.
   PubMed Web of Science ®Google Scholar
• Habashy HO, Powe DG, Staka CM, et al. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat. 2010;119:283–293.
   PubMed Web of Science ®Google Scholar
• Hann HW, Stahlhut MW, Blumberg BS. Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. Cancer Res. 1988;48:4168–4170.
   PubMed Web of Science ®Google Scholar
• Ceci A, Felisi M, De Sanctis V, et al. Pharmacotherapy of iron overload in thalassaemic patients. Expert Opin Pharmacother. 2003;4:1763–1774.
   PubMed Web of Science ®Google Scholar
• Fukuchi K, Tomoyasu S, Tsuruoka N, et al. Iron deprivation-induced apoptosis in HL-60 cells. FEBS Lett. 1994;350:139–142.
   PubMed Web of Science ®Google Scholar
• Fan L, Iyer J, Zhu S, et al. Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells. Cancer Res. 2001;61:1073–1079.
   PubMed Web of Science ®Google Scholar
• Rosilio C, Nebout M, Imbert V, et al. L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia. Leukemia. 2015;29:1253–1266.
   PubMed Web of Science ®Google Scholar
• Ponka P, Lok CN. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol. 1999;31:1111–1137.
   PubMed Web of Science ®Google Scholar
• Daniels TR, Delgado T, Helguera G, et al. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol. 2006;121:159–176.
   PubMed Web of Science ®Google Scholar
• Ned RM, Swat W, Andrews NC. Transferrin receptor 1 is differentially required in lymphocyte development. Blood. 2003;102:3711–3718.
   PubMed Web of Science ®Google Scholar
• Daniels TR, Bernabeu E, Rodríguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012;1820:291–317.
   PubMed Web of Science ®Google Scholar
• Barnett D, Wilson GA, Lawrence AC, et al. Transferrin receptor expression in the leukaemias and lymphoproliferative disorders. Clin Lab Haematol. 1987;9:361–370.
   PubMedGoogle Scholar
• Taetle R, Ralph S, Smedsrud S, et al. Regulation of transferrin receptor expression in myeloid leukemia cells. Blood. 1987;70:852–859.
   PubMed Web of Science ®Google Scholar
• Das Gupta A, Patil J, Shah VI. Transferrin receptor expression by blast cells in acute lymphoblastic leukemia correlates with white cell count & immunophenotype. Indian J Med Res. 1996;104:226–233.
   PubMed Web of Science ®Google Scholar
• Glasová M, Koníková E, Stasáková J, et al. The relationship of HLA-DR, CD38 and CD71 markers to activation, proliferation and differentiation of some human leukemia and lymphoma cells. Neoplasma. 1998;45:88–95.
   PubMed Web of Science ®Google Scholar
• Koehler M, Behm F, Hancock M, et al. Expression of activation antigens CD38 and CD71 is not clinically important in childhood acute lymphoblastic leukemia. Leukemia. 1993;7:41–45.
   PubMed Web of Science ®Google Scholar
• Edinger AL, Thompson CB. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell. 2002;13:2276–2288.
   PubMed Web of Science ®Google Scholar
• Bayeva M, Khechaduri A, Puig S, et al. mTOR regulates cellular iron homeostasis through tristetraprolin. Cell Metab. 2012;16:645–657.
   PubMed Web of Science ®Google Scholar
• Ndong M, Kazami M, Suzuki T, et al. Iron deficiency down-regulates the Akt/TSC1-TSC2/mammalian Target of Rapamycin signaling pathway in rats and in COS-1 cells. Nutr Res. 2009;29:640–647.
   PubMed Web of Science ®Google Scholar
• Ohyashiki JH, Kobayashi C, Hamamura R, et al. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci. 2009;100:970–977.
   PubMed Web of Science ®Google Scholar
• Mourad YA, Taher A, Chehal A, et al. Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody. Ann Hematol. 2004;83:319–321.
   PubMed Web of Science ®Google Scholar
• Crépin R, Goenaga AL, Jullienne B, et al. Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas. Cancer Res. 2010;70:5497–5506.
   PubMed Web of Science ®Google Scholar
• Richardson D, Ponka P, Baker E. The effect of the iron(III) chelator, deferoxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res. 1994;54:685–689.
   PubMed Web of Science ®Google Scholar
• Keberle H. The biochemistry of Desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci. 1964;119:758–768.
   PubMed Web of Science ®Google Scholar
• Donfrancesco A, Deb G, Dominici C, et al. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res. 1990;50:4929–4930.
   PubMed Web of Science ®Google Scholar
• Hatcher HC, Singh RN, Torti FM, et al. Synthetic and natural iron chelators: therapeutic potential and clinical use. Future Med Chem. 2009;1:1643–1670.
   PubMed Web of Science ®Google Scholar
• Fang D, Bao Y, Li X, et al. Effects of iron deprivation on multidrug resistance of leukemic K562 cells. Chemotherapy. 2010;56:9–16.
   PubMed Web of Science ®Google Scholar
• Callens C, Coulon S, Naudin J, et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med. 2010;207:731–750.
   PubMed Web of Science ®Google Scholar
• Ford SJ, Obeidy P, Lovejoy DB, et al. Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo. Br J Pharmacol. 2013;168:1316–1328.
   PubMed Web of Science ®Google Scholar
• Vazana-Barad L, Granot G, Mor-Tzuntz R, et al. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma. Leuk Lymphoma. 2013;54:851–859.
   PubMed Web of Science ®Google Scholar
• Paubelle E, Zylbersztejn F, Alkhaeir S, et al. Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure. PLoS One. 2013;8:e65998.
   PubMed Web of Science ®Google Scholar
• Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013;13:342–355.
   PubMed Web of Science ®Google Scholar
• Nyholm S, Mann GJ, Johansson AG, et al. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J Biol Chem. 1993;268:26200–26205.
   PubMed Web of Science ®Google Scholar
• Lane DJ, Mills TM, Shafie NH, et al. Expanding horizons in iron chelation and the treatment of cancer: role of iron in the regulation of ER stress and the epithelial-mesenchymal transition. Biochim Biophys Acta. 2014;1845:166–181.
   PubMed Web of Science ®Google Scholar
• Le NT, Richardson DR. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood. 2004;104:2967–2975.
   PubMed Web of Science ®Google Scholar
• Kim JL, Lee DH, Na YJ, etet al. Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells. Tumor Biol. 2016;37:9709–9719.
   PubMed Web of Science ®Google Scholar
• Tataranni T, Agriesti F, Mazzoccoli C, et al. The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells. Br J Haematol. 2015;170:236–246.
   PubMed Web of Science ®Google Scholar
• Al-Shabanah OA, Aleisa AM, Hafez MM, et al. Deferoxamine attenuates doxorubicin-induced acute cardiotoxicity through TFG-β/Smad p53 pathway in rat model. Oxid Med Cell Longev. 2012;2012:619185.
   PubMed Web of Science ®Google Scholar